This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2000 May;163(5):1600.

Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide

PMID: 10798919

Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide

M J Droller. J Urol. 2000 May.

. 2000 May;163(5):1600.

Author

PMID: 10798919

No abstract available

PubMed Disclaimer

Similar articles

Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ, Saunders MI, Dische S. Hoskin PJ, et al. Cancer. 1999 Oct 1;86(7):1322-8. Cancer. 1999. PMID: 10506720 Clinical Trial.
Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ; BCON investigators. Hoskin PJ, et al. Radiother Oncol. 2009 Apr;91(1):120-5. doi: 10.1016/j.radonc.2008.10.001. Epub 2008 Nov 5. Radiother Oncol. 2009. PMID: 18992952 Clinical Trial.
Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.
Saunders M, Dische S. Saunders M, et al. Br J Cancer Suppl. 1996 Jul;27:S271-8. Br J Cancer Suppl. 1996. PMID: 8763896 Free PMC article. Review.
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Hoskin PJ, Saunders MI, Phillips H, Cladd H, Powell ME, Goodchild K, Stratford MR, Rojas A. Hoskin PJ, et al. Br J Cancer. 1997;76(2):260-3. doi: 10.1038/bjc.1997.372. Br J Cancer. 1997. PMID: 9231929 Free PMC article. Clinical Trial.
ARCON--current status: summary of a workshop on preclinical and clinical studies.
Denekamp J, Fowler JF. Denekamp J, et al. Acta Oncol. 1997;36(5):517-25. doi: 10.3109/02841869709001308. Acta Oncol. 1997. PMID: 9292749 Review.

See all similar articles

Cited by

Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma.
Win KT, Lee SW, Huang HY, Lin LC, Lin CY, Hsing CH, Chen LT, Li CF. Win KT, et al. Tumour Biol. 2013 Dec;34(6):3923-31. doi: 10.1007/s13277-013-0980-z. Epub 2013 Jul 11. Tumour Biol. 2013. PMID: 23838801
Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts.
Tang R, Zhu J, Liu Y, Wu N, Han J. Tang R, et al. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036324. doi: 10.1177/15330338211036324. Technol Cancer Res Treat. 2021. PMID: 34433326 Free PMC article.
Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review.
Togni L, Mascitti M, Sartini D, Campagna R, Pozzi V, Salvolini E, Offidani A, Santarelli A, Emanuelli M. Togni L, et al. Biomolecules. 2021 Oct 28;11(11):1594. doi: 10.3390/biom11111594. Biomolecules. 2021. PMID: 34827592 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information